NFATC1 and cancer: Mechanistically, our findings reveal that manidipine reduces drug efflux activity in resistant cancer cells by modulating intracellular calcium concentrations and targeting nuclear factor of activated T cells 2 (NFAT2), ultimately re-sensitizing these cells to chemotherapy.